Search Results
Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL
Dr. Goy Compares Acalabrutinib With Ibrutinib in MCL
Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL
Dr. Goy on Promising Data With Acalabrutinib in MCL
Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCL
Dr. Wang on the Toxicity of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL
Dr. Goy Discusses Single-Agent Ibrutinib in MCL
Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL
Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL
Acalabrutinib Versus Ibrutinib for CLL
First results of head-to-head acalabrutinib versus ibrutinib in CLL
Dr. Goy on the Progression of MCL Treatment